3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hematopoietic and Lymphatic System Neoplasm
3
Neoplasms
2
Malignant Solid Neoplasm
2
Lung Neoplasms
2
Breast Neoplasms
2
Spondylitis, Ankylosing
1
Smoking Cessation
1
Sarcoma
1
Pyloric Stenosis, Hypertrophic
1
Psoriasis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Mental Disorders
1
Melanoma
1
Malignant Female Reproductive System Neoplasm
1
Lupus Erythematosus, Systemic
1
Localized Head and Neck Carcinoma
1
Laryngeal Neoplasms
1
Inflammatory Bowel Diseases
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Depressive Disorder
1
Depression
1
Crohn Disease
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
7
Specimen Handling
5
trametinib
3
fludarabine
3
Tacrolimus
3
Standard of Care
3
Mycophenolic Acid
3
Magnetic Resonance Spectroscopy
3
GSK2636771
3
Biopsy
3
venetoclax
2
talquetamab
2
ruxolitinib
2
fludarabine phosphate
2
dabrafenib
2
capivasertib
2
binimetinib
2
adavosertib
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Nivolumab
2
Crizotinib
2
Ado-Trastuzumab Emtansine
2
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sapanisertib
1
relatlimab
1
rasburicase
1
plerixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Interviews as Topic
×
30 days
×
Clear all
No trials found.